Compare · GLP-1 agonist
Semaglutide vs VK2735
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Semaglutide | VK2735 | |
|---|---|---|
| Evidence | 10/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. | VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown. |
| Full profile → | Full profile → |
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.
VK2735
VK2735 is an experimental obesity drug from a company called Viking Therapeutics. It's part of the incretin family (a group of gut-hormone-based drugs that turn down appetite) — the same broad family as semaglutide and tirzepatide. It has drawn a lot of buzz for two reasons: its early results in…